Last reviewed · How we verify

Dose D3 of interleukin-2

Assistance Publique - Hôpitaux de Paris · Phase 2 active Small molecule

Dose D3 of interleukin-2 is a Cytokine Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 2 development for Melanoma, Renal cell carcinoma.

Interleukin-2 stimulates T-cell proliferation and activation.

Interleukin-2 stimulates T-cell proliferation and activation. Used for Melanoma, Renal cell carcinoma.

At a glance

Generic nameDose D3 of interleukin-2
SponsorAssistance Publique - Hôpitaux de Paris
Drug classCytokine
TargetInterleukin-2 receptor
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

Interleukin-2 is a cytokine that plays a crucial role in the immune response, particularly in the activation and proliferation of T-cells. It is used to treat various types of cancer, including melanoma and renal cell carcinoma.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dose D3 of interleukin-2

What is Dose D3 of interleukin-2?

Dose D3 of interleukin-2 is a Cytokine drug developed by Assistance Publique - Hôpitaux de Paris, indicated for Melanoma, Renal cell carcinoma.

How does Dose D3 of interleukin-2 work?

Interleukin-2 stimulates T-cell proliferation and activation.

What is Dose D3 of interleukin-2 used for?

Dose D3 of interleukin-2 is indicated for Melanoma, Renal cell carcinoma.

Who makes Dose D3 of interleukin-2?

Dose D3 of interleukin-2 is developed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

What drug class is Dose D3 of interleukin-2 in?

Dose D3 of interleukin-2 belongs to the Cytokine class. See all Cytokine drugs at /class/cytokine.

What development phase is Dose D3 of interleukin-2 in?

Dose D3 of interleukin-2 is in Phase 2.

What are the side effects of Dose D3 of interleukin-2?

Common side effects of Dose D3 of interleukin-2 include Flu-like symptoms, Fatigue, Nausea.

What does Dose D3 of interleukin-2 target?

Dose D3 of interleukin-2 targets Interleukin-2 receptor and is a Cytokine.

Related